It could be explained by the fact that activating both mechanisms—T cell activation by atezolizumab and the interferon γ-mediated induction of PD-L1 expression—throw the reprogramming tumor microenvironment into the active immune system by VEGFR inhibitor [57]. The gene discussed is KDR; the disease is neoplasm.